Last reviewed · How we verify
NCT05338047
Efficacy of Generic Pegfilgrastim vs Brand Name Pegfilrastim for Neutrophil Recovery After Autotransplant
Phase 2 trial testing Pegfilgrastim in Myeloma Multiple in 30 participants. Completed in 25 February 2023.
25 February 2023
Quick facts
| Lead sponsor | Hospital Universitario Dr. Jose E. Gonzalez |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 30 |
| Start date | 1 April 2022 |
| Primary completion | 25 February 2023 |
| Estimated completion | 25 February 2023 |
| Sites | 1 location across Mexico |
Drugs / interventions tested
- Pegfilgrastim (PEGFILGRASTIM) — full drug profile →
Conditions studied
- Myeloma Multiple — all drugs for Myeloma Multiple →
- Lymphoma — all drugs for Lymphoma →
Sponsor
Hospital Universitario Dr. Jose E. Gonzalez
Who can join
Adults 18 to 90, any sex, with Myeloma Multiple or Lymphoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a phase 2 clinical trial comparing time to neutrophil recovery after autotrasplant using generic pegfilgrastim vs brand-name pegfilgrastim.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05338047
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Pegfilgrastim
Trials testing the same drug.
- NCT07021989 — ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma · Phase 2 · not yet recruiting
- NCT06738368 — Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombin · Phase 2 · recruiting
- NCT07278856 — Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphoma · Phase 1 · not yet recruiting
- NCT07059611 — Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma · Phase 2 · not yet recruiting
- NCT07224100 — Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosom · Phase 2 · recruiting
Other recruiting trials for Myeloma Multiple
Currently open trials in the same condition.
- NCT07236021 — e-Motion : Promoting Emotion Regulation in Chronic Cancer · NA · recruiting
- NCT06245629 — Bortezomib-bendamustine-melphalan vs Melphalan for Multiple Myeloma · recruiting
- NCT06911710 — The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors · Phase 1, PHASE2 · recruiting
- NCT05889221 — Multicenter Phase 2 Study of Subcutaneous Isatuximab Plus Bortezomib, Lenalidomide and Dexamethasone in the Treatment of · NA · active not recruiting
- NCT05651932 — A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma · Phase 1 · recruiting
Other Hospital Universitario Dr. Jose E. Gonzalez trials
Trials by the same sponsor.
- NCT07401992 — Effects of Semaglutide on Clinical Outcomes and Metabolic Inflammation in Psoriasis · Phase 4 · recruiting
- NCT06758375 — Low Dose Teclistamab in Newly Diagnosed Multiple Myeloma Patients · Phase 2 · recruiting
- NCT06904599 — Efficacy of Human Chorionic Gonadotropin in Acute GVHD Treatment · Phase 2 · recruiting
- NCT07039877 — Efficacy of Low-dose Venetoclax With Itraconazole + TACL for R/R ALL Patients · Phase 2 · recruiting
- NCT06209190 — Safety and Feasibility of TMLI as Conditioning Regimen in Allogeneic Hematopoietic Stem-cell Transplantation · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05338047 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hospital Universitario Dr. Jose E. Gonzalez
- Last refreshed: 28 February 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05338047.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing